Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
AstraZeneca's Baxdrostat makes its case
08:48am, Monday, 01'st Sep 2025
Among the noise of tariffs, drug pricing reforms, and shifting investor sentiment, AstraZeneca PLC (LSE:AZN) has quietly delivered a clear result: its experimental blood pressure treatment, baxdrosta
AstraZeneca to seek approval for blood pressure drug by year-end
10:23am, Saturday, 30'th Aug 2025
AstraZeneca plans to file for regulatory approval of its experimental blood pressure treatment before the end of the year, a senior company executive said, about a product seen as key to the drugmaker
AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results
10:15am, Saturday, 30'th Aug 2025
AstraZeneca, on Saturday, unveiled promising results for a new hypertension treatment that aims to help the roughly 650,000 people with uncontrolled high blood pressure.
Grab These 4 Safe DJIA Dividend Bargains After Index Hits All-Time Highs
09:34am, Tuesday, 26'th Aug 2025
The Dow Jones Industrial Average (DJIA) is one of the oldest and most widely recognized stock market indices in the world.
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Pharmacy Services, a leading provider of long-term care and specialty pharmacy solutions, has been selected as the exclusive U.S. distributor for FluMis
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs
11:01am, Friday, 15'th Aug 2025
AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.
The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce. FAIRFIELD, N.J.
AstraZeneca: Great Portfolio, But Not A Great Price
11:16am, Monday, 11'th Aug 2025
AstraZeneca PLC boasts strong 2024 results with $54B revenue and 14 blockbuster drugs, driven by robust growth in oncology and rare disease franchises. Key products like Farxiga, Tagrisso, and Ultomir
Ex-dividend day weighs heavily on the FTSE this week
03:38am, Thursday, 07'th Aug 2025
Thursday is ex-dividend day in London and this week there was a heavyweight billing that knocked the FTSE 100 sideways, including companies such as AstraZeneca PLC (LSE:AZN), NatWest Group PLC (LSE:
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
06:40am, Tuesday, 05'th Aug 2025
BOSTON and ROLLE, Switzerland , Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
11:41am, Friday, 01'st Aug 2025
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
10:51am, Friday, 01'st Aug 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
